Search

Author/Creator Yu, Y.

2. 103P Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of Chinese extensive-stage small cell lung cancer (ORIENTAL): Preliminary safety and efficacy results. (December 2022)

Authors:
Cheng, Y.; Wang, J.; Yu, Y.; Zang, A.; Lv, D.; Li, S.; Cao, L.; Meng, Z.; Mao, W.D.; Zhang, J.; Liu, A.; Zhang, Y.; Tang, K.; Liu, J.; Zheng, J.; Wang, Z.; Chen, E.; Zhang, X.; Guo, Q.; Huang, D.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 132P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small cell lung cancer (sq-NSCLC): RATIONALE-307 updated analysis. (December 2022)

Authors:
Wang, J.; Lu, S.; Yu, X.; Hu, Y.; Zhao, J.; Sun, M.L.; Yu, Y.; Hu, C.; Yang, K.; Song, Y.; Lin, X.; Liang, L.; Leaw, S.; Zheng, W.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. 138P Randomized phase III study of tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced non-squamous non-small cell lung cancer (nsq-NSCLC): RATIONALE-304 updated analysis. (December 2022)

Authors:
Lu, S.; Wang, J.; Yu, Y.; Yu, X.; Hu, Y.; Ma, Z.; Li, X.; He, W.; Bao, Y.; Wang, M.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). (December 2022)

Authors:
Zhang, J.; Hussein, M.; Kao, S.C-H.; Clay, T.D.; Singhal, N.; Kim, H.R.; Cho, E.K.; Shim, B.; Lee, Y.; Lee, G-W.; Zhao, J.; Yu, Y.; Sun, M.; Lin, C-B.; Yang, T-Y.; Chang, G-C.; Zheng, H.; Tan, W.; Spigel, D.R.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. 71P Real-world treatment patterns and clinical outcomes for patients who received sintilimab (Sint) in first-line treatment of advanced non-small cell lung cancer (NSCLC) in China: A multicenter retrospective observational study. (December 2022)

Authors:
Yu, Y.; Shang, L.; Xie, Q.; Ying, K.; Jin, B.; Zhang, L.; Liu, L.; Li, J.; Ding, W.
Journal:
Immuno-oncology technology
Issue:
Volume 16(2022)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗